Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation

Next Previous
Trial Profile

A phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study of naldemedine in cancer patients with opioid-induced constipation

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Naldemedine (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Acronyms COMPOSE IV
  • Sponsors Shionogi

    • Most Recent Events

    • 22 Feb 2019 According to a Shionogi media release, European Commission (EC) granted a Marketing Authorisation (MA) for Rizmoic (naldemedine), for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235).
    • 18 Dec 2018 According to a Shionogi media release, based on data from three phase 3 efficacy and safety studies (V9231, V9232 and V9236) and one long term safety study (V9235), the CHMP has adopted a positive opinion recommending Rizmoic (naldemedine), for the treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative. The EC will issue a decision in due course for naldemedine, taking into account the recommendation from the CHMP.
    • 02 Oct 2017 Results published in the Journal of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top